Guardant Health (GH) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

Financial Performance & Growth - Guardant Health shows a strong Compound Annual Growth Rate (CAGR) of 59%[9] - The company's revenue increased from $91 million in 2018 to between $360 million and $370 million in 2021[9] - The company has $1.7 billion in cash, cash equivalents, and marketable securities as of September 30, 2021[10] Product Development & Clinical Trials - Guardant Health's ECLIPSE trial has reached its target enrollment[7, 32] - The company initiated the SHIELD lung study and enrolled the first patient[7] - The ORACLE study is evaluating Guardant Reveal to predict cancer recurrence after curative intent treatment, targeting ~1,000 individuals across 11 solid tumor types[7, 21, 22] - A next-generation Guardant SHIELD assay is under development, with a ~30x larger genomic footprint than the original panel[41] Market & Commercial Expansion - The company has partnerships with over 100 biopharma companies[8, 10, 47] - Over 250,000 tests have been ordered, and more than 11,000 oncologists are ordering Guardant Health's tests[7, 10] - The company is expanding internationally, with lab partners in the UK & Spain and regulatory approval being pursued in Japan[7] - The company has secured coverage for over 200 million lives[8] Technology & Innovation - Guardant Health is developing a "Smart Liquid Biopsy" with a nearly 100X larger genomic footprint than Guardant360 CDx, including genomic, epigenomic, and immune signatures, expected in 2022[28] - The company's technology integrates genomic and epigenomic ctDNA signals, increasing sensitivity by 1.3-2.5x[25] - Guardant Health's digital sequencing enables early detection with higher signal-to-noise ratio and lower sequencing cost[29] Screening and MRD Market Opportunity - The Minimal Residual Disease (MRD) market represents a $20B+ Total Addressable Market (TAM)[13, 24] - The therapy selection market is estimated at $6 billion, the MRD market at $10 billion, and the early-stage survivors market at $15 billion[26] - Blood-based screening is preferred by 64% of patients for CRC screening, compared to 36% for colonoscopy, FIT, or Cologuard[37]